Agenus, Inc.

In 2015, we announced a global license, development, and commercialization agreement with Agenus Inc. focused on novel immuno-therapeutics using Agenus Inc.’s proprietary Retrocyte Display antibody discovery platform. The alliance will initially focus on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3, and TIM-3.